Table 2.
Preclinical studies: antipsychotic-like effects of cannabidiol.
| Model | Species | CBD effect (dose range in mg/kg) | Clozapine effect | Haloperidol effect | References |
|---|---|---|---|---|---|
| “DOPAMINERGIC” MODELS | |||||
| Stereotypies induced by DA agonists | Rats |
 (60) |
N.T. | |
(65) |
| Prolactin levels | Rats | =( only in high doses: 120–240) |
N.T. | |
(65) |
| Catalepsy | Rats, mice | = | = | |
(66) |
| Hyperlocomotion induced by amphetamine | Mice |
(30–60) |
|
|
(67) |
| cFos expression | Rats |
accumbens and mPFC (120) |
accumbens and mPFC |
accumbens and striatum |
(68) |
| PPI impairment by amphetamine | Mice |
(15–60) |
|
|
(69) |
| “GLUTAMATERGIC” MODELS | |||||
| Hyperlocomotion induced by ketamine | Mice |
(15–60, bell-shaped dose-response curve) |
|
|
(67) |
| PPI impairment by MK801 (21 days)* | Mice |
(30–60 daily, for 21 days) |
|
N.T. | (70) |
DA, dopamine; mPFC, medial prefrontal cortex; N.T., not tested;
*
repeated CBD also prevented memory (measured with the object recognition test) and social interaction impairment induced by repeated MK801. Reduction (or decrease), Increase.